Literature DB >> 2184369

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

H Takahashi1, T Takeshita, B Morein, S Putney, R N Germain, J A Berzofsky.   

Abstract

To reduce the risks of immunization with killed or live attenuated virus vaccines, it may be advantageous to use a pure, defined antigen that contains determinants for both humoral and cellular immunity. However, although most non-living intact protein preparations induce antibodies and CD4+ major histocompatibility complex (MHC) class II-restricted helper and/or cytotoxic T lymphocytes (CTL), they do not elicit CD8+ MHC class I restricted CTL. Indeed, with a few exceptions, it has not so far been possible to induce CD8+ CTL by immunizing with intact soluble proteins. We show here that a single subcutaneous immunization in mice with immunostimulating complexes containing either purified intact gp160 envelope glycoprotein of the human immunodeficiency virus (HIV)-1 or influenza haemagglutinin results in reproducible and long-lasting priming of HIV specific or influenza-specific CD8+, MHC class I restricted CTL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184369     DOI: 10.1038/344873a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  80 in total

1.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.

Authors:  A M Mowat; A M Donachie; G Reid; O Jarrett
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.

Authors:  M C Aldhous; K C Watret; J Y Mok; A G Bird; K S Froebel
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 6.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Expression and characterization of virus-like particles containing rubella virus structural proteins.

Authors:  Z Qiu; D Ou; T C Hobman; S Gillam
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.

Authors:  X Zhou; P Berglund; H Zhao; P Liljeström; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.